• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于神经肌肉疾病的运动功能测量方法。构建与验证研究。

A motor function measure for neuromuscular diseases. Construction and validation study.

作者信息

Bérard Carole, Payan Christine, Hodgkinson Isabelle, Fermanian Jacques

机构信息

Department of Paediatric Rehabilitation, l'Escale, Centre Hospitalier Lyon-Sud, France.

出版信息

Neuromuscul Disord. 2005 Jul;15(7):463-70. doi: 10.1016/j.nmd.2005.03.004.

DOI:10.1016/j.nmd.2005.03.004
PMID:16106528
Abstract

A new scale for motor function measurement has been developed for neuromuscular diseases. The validation study included 303 patients, aged 6-62 years. Seventy-two patients had Duchenne muscular dystrophy, 32 Becker muscular dystrophy, 30 limb-girdle muscular dystrophy, 39 facio-scapulo-humeral dystrophy, 29 myotonic dystrophy, 21 congenital myopathy, 10 congenital muscular dystrophy, 35 spinal muscular atrophy and 35 hereditary neuropathy. The scale comprised 32 items, in three dimensions: standing position and transfers, axial and proximal motor function, distal motor function. Agreement coefficients for inter-rater reliability were excellent (kappa=0.81-0.94) for nine items, good (kappa=0.61-0.80) for 20 items and moderate (kappa=0.51-0.60) for three items. High correlations were found between the total score and other scores: Vignos (r=0.91) and Brooke (r=0.85) grades, Functional Independence Measure (r=0.91), the global severity of disability evaluated with visual analog scales by physicians (r=0.88) and physiotherapists (r=0.91). This scale is reliable, does not require any special equipment and is well-accepted by patients. Its sensitivity to change is being assessed to permit its use in clinical trials of neuromuscular diseases.

摘要

一种用于测量神经肌肉疾病运动功能的新量表已被开发出来。验证研究纳入了303名年龄在6至62岁之间的患者。其中72名患有杜氏肌营养不良症,32名患有贝克肌营养不良症,30名患有肢带型肌营养不良症,39名患有面肩肱型肌营养不良症,29名患有强直性肌营养不良症,21名患有先天性肌病,10名患有先天性肌营养不良症,35名患有脊髓性肌萎缩症以及35名患有遗传性神经病。该量表包含32个项目,分为三个维度:站立姿势与转移、轴向和近端运动功能、远端运动功能。评分者间信度的一致性系数在9个项目中为优(kappa = 0.81 - 0.94),20个项目中为良(kappa = 0.61 - 0.80),3个项目中为中等(kappa = 0.51 - 0.60)。在总分与其他评分之间发现了高度相关性:Vignos评分(r = 0.91)和Brooke评分(r = 0.85)、功能独立性测量(r = 0.91)、医生用视觉模拟量表评估的残疾总体严重程度(r = 0.88)以及物理治疗师评估的结果(r = 0.91)。该量表可靠,不需要任何特殊设备,且患者接受度良好。目前正在评估其对变化的敏感性,以便能用于神经肌肉疾病的临床试验。

相似文献

1
A motor function measure for neuromuscular diseases. Construction and validation study.一种用于神经肌肉疾病的运动功能测量方法。构建与验证研究。
Neuromuscul Disord. 2005 Jul;15(7):463-70. doi: 10.1016/j.nmd.2005.03.004.
2
[A motor function measurement scale for neuromuscular diseases - description and validation study].
Rev Neurol (Paris). 2006 Apr;162(4):485-93. doi: 10.1016/s0035-3787(06)75039-1.
3
[Validity of the motor function measurement scale when routinely used in the follow-up of adult outpatients in a neuromuscular center].[运动功能测量量表在神经肌肉中心成年门诊患者随访中的常规应用效度]
Rev Neurol (Paris). 2010 Jan;166(1):49-53. doi: 10.1016/j.neurol.2009.05.005. Epub 2009 Jun 12.
4
Development and validation of a motor function classification in patients with neuromuscular disease: the NM-score.神经肌肉疾病患者运动功能分类的制定和验证:NM 评分。
Ann Phys Rehabil Med. 2013 Dec;56(9-10):673-86. doi: 10.1016/j.rehab.2013.10.002. Epub 2013 Oct 18.
5
Turkish version of the Motor Function Measure Scale (MFM-32) forneuromuscular diseases: a cross-cultural adaptation, reliability, and validity study.《运动功能测量量表(MFM-32)土耳其语版用于神经肌肉疾病:跨文化调适、信度和效度研究》。
Turk J Med Sci. 2017 Dec 19;47(6):1826-1833. doi: 10.3906/sag-1603-91.
6
Development and validation of a muscular dystrophy-specific functional rating scale.一种肌肉萎缩症特异性功能评定量表的开发与验证
Clin Rehabil. 2006 Sep;20(9):804-17. doi: 10.1177/0269215506070809.
7
Measurement of the functional status of patients with different types of muscular dystrophy.不同类型肌营养不良患者功能状态的测量。
Kaohsiung J Med Sci. 2009 Jun;25(6):325-33. doi: 10.1016/S1607-551X(09)70523-6.
8
English cross-cultural translation and validation of the neuromuscular score: a system for motor function classification in patients with neuromuscular diseases.神经肌肉评分的英文跨文化翻译与验证:一种用于神经肌肉疾病患者运动功能分类的系统。
Arch Phys Med Rehabil. 2014 Nov;95(11):2064-2070.e1. doi: 10.1016/j.apmr.2014.05.003. Epub 2014 May 24.
9
Motor function measure: validation of a short form for young children with neuromuscular diseases.运动功能测量:适用于神经肌肉疾病幼儿的简短形式的验证。
Arch Phys Med Rehabil. 2013 Nov;94(11):2218-26. doi: 10.1016/j.apmr.2013.04.001. Epub 2013 Apr 18.
10
Upper vs lower extremity functional loss in neuromuscular disease.神经肌肉疾病中上肢与下肢功能丧失的比较
Arch Phys Med Rehabil. 1987 Jan;68(1):8-9.

引用本文的文献

1
The Facioscapulohumeral Muscular Dystrophy Rasch-Built Overall Disability Scale (FSHD-RODS): Longitudinal Assessment of a Disease-Specific Patient Reported Outcome.面肩肱型肌营养不良症拉施构建总体残疾量表(FSHD-RODS):针对特定疾病的患者报告结局的纵向评估
Eur J Neurol. 2025 Aug;32(8):e70238. doi: 10.1111/ene.70238.
2
Application of Real-World Evidence to Support FDA Regulatory Decision Making.应用真实世界证据支持美国食品药品监督管理局的监管决策
AAPS J. 2025 May 28;27(4):98. doi: 10.1208/s12248-025-01082-1.
3
Effect of creatine monohydrate on motor function in children with facioscapulohumeral muscular dystrophy: A multicenter, randomized, double-blind placebo-controlled crossover trial.
一水肌酸对面肩肱型肌营养不良症患儿运动功能的影响:一项多中心、随机、双盲、安慰剂对照的交叉试验。
Pharmacotherapy. 2025 Jun;45(6):341-351. doi: 10.1002/phar.70025. Epub 2025 May 14.
4
High-intensity resistance training in patients with myositis - 1-year follow-up on a randomised controlled trial.肌炎患者的高强度抗阻训练——一项随机对照试验的1年随访
Rheumatol Int. 2025 Apr 16;45(5):104. doi: 10.1007/s00296-025-05858-8.
5
Use of assistive technology to assess distal motor function in subjects with neuromuscular disease.使用辅助技术评估神经肌肉疾病患者的远端运动功能。
PLOS Digit Health. 2025 Jan 13;4(1):e0000534. doi: 10.1371/journal.pdig.0000534. eCollection 2025 Jan.
6
Spinal cord gray matter atrophy is associated with disability in spinal muscular atrophy.脊髓灰质萎缩与脊髓性肌萎缩症中的残疾相关。
J Neurol. 2025 Jan 7;272(1):102. doi: 10.1007/s00415-024-12740-3.
7
A 5-year natural history cohort of patients with facioscapulohumeral muscular dystrophy determining disease progression and feasibility of clinical outcome assessments for clinical trials.一项关于面肩肱型肌营养不良患者的5年自然史队列研究,以确定疾病进展及临床试验临床结局评估的可行性。
Muscle Nerve. 2025 Jan;71(1):55-62. doi: 10.1002/mus.28293. Epub 2024 Nov 7.
8
A 5-year natural history study in LAMA2-related muscular dystrophy and SELENON-related myopathy: the Extended LAST STRONG study.LAMA2 相关肌营养不良症和 SELENON 相关肌病的 5 年自然病史研究:扩展 LAST STRONG 研究。
BMC Neurol. 2024 Oct 23;24(1):409. doi: 10.1186/s12883-024-03852-4.
9
Cultural adaptation, validity and reliability of the Turkish version of north star ambulatory assessment.《北极星动态评估土耳其语版的文化适应性、效度和信度》
Acta Neurol Belg. 2025 Feb;125(1):127-132. doi: 10.1007/s13760-024-02670-2. Epub 2024 Oct 22.
10
Taldefgrobep Alfa and the Phase 3 RESILIENT Trial in Spinal Muscular Atrophy.阿尔法和脊髓性肌萎缩症 3 期 RESILIENT 试验的 Taldefgrobep。
Int J Mol Sci. 2024 Sep 24;25(19):10273. doi: 10.3390/ijms251910273.